Sarepta Therapeutics, Inc. (SRPT): Price and Financial Metrics

Sarepta Therapeutics, Inc. (SRPT): $68.49

-0.35 (-0.51%)

POWR Rating

Component Grades













Add SRPT to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where SRPT ranks best; there it ranks ahead of 95.36% of US stocks.
  • The strongest trend for SRPT is in Growth, which has been heading up over the past 179 days.
  • SRPT ranks lowest in Momentum; there it ranks in the 12th percentile.

SRPT Stock Summary

  • Of note is the ratio of Sarepta Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 11.72% of US stocks have a lower such ratio.
  • With a price/sales ratio of 9.77, Sarepta Therapeutics Inc has a higher such ratio than 84.94% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 4.69 for Sarepta Therapeutics Inc; that's greater than it is for 78.03% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sarepta Therapeutics Inc are CGEN, IDYA, WVE, PLRX, and PRQR.
  • Visit SRPT's SEC page to see the company's official filings. To visit the company's web site, go to

SRPT Valuation Summary

  • In comparison to the median Healthcare stock, SRPT's price/sales ratio is 8.37% lower, now standing at 10.4.
  • SRPT's price/earnings ratio has moved up 3.9 over the prior 243 months.
  • SRPT's price/sales ratio has moved down 648 over the prior 243 months.

Below are key valuation metrics over time for SRPT.

Stock Date P/S P/B P/E EV/EBIT
SRPT 2021-08-31 10.4 12.9 -9.8 -9.0
SRPT 2021-08-30 10.1 12.5 -9.5 -8.7
SRPT 2021-08-27 10.5 13.0 -9.9 -9.1
SRPT 2021-08-26 10.4 12.9 -9.9 -9.0
SRPT 2021-08-25 10.6 13.2 -10.1 -9.2
SRPT 2021-08-24 10.3 12.7 -9.7 -8.9

SRPT Growth Metrics

    Its year over year cash and equivalents growth rate is now at -16.01%.
  • Its 4 year cash and equivalents growth rate is now at 4448.81%.
  • The 5 year net cashflow from operations growth rate now stands at 290.38%.
Over the past 34 months, SRPT's revenue has gone up $378,446,000.

The table below shows SRPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 701.887 -443.172 -418.78
2021-09-30 645.564 -588.381 -486.116
2021-06-30 600.082 -702.238 -634.471
2021-03-31 573.356 -700.695 -703.886
2020-12-31 540.099 107.466 -554.128
2020-09-30 495.074 118.206 -600.514

SRPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SRPT has a Quality Grade of C, ranking ahead of 59.75% of graded US stocks.
  • SRPT's asset turnover comes in at 0.231 -- ranking 185th of 682 Pharmaceutical Products stocks.
  • ORMP, AGIO, and JAZZ are the stocks whose asset turnover ratios are most correlated with SRPT.

The table below shows SRPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.231 0.864 -0.249
2021-06-30 0.213 0.868 -0.332
2021-03-31 0.201 0.872 -0.375
2020-12-31 0.186 0.883 -0.313
2020-09-30 0.190 0.886 -0.376
2020-06-30 0.192 0.879 -0.357

SRPT Price Target

For more insight on analysts targets of SRPT, see our SRPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $118.39 Average Broker Recommendation 1.5 (Moderate Buy)

SRPT Stock Price Chart Interactive Chart >

Price chart for SRPT

SRPT Price/Volume Stats

Current price $68.49 52-week high $101.24
Prev. close $68.84 52-week low $61.28
Day low $67.80 Volume 538,185
Day high $70.50 Avg. volume 906,031
50-day MA $76.14 Dividend yield N/A
200-day MA $80.10 Market Cap 5.99B

Sarepta Therapeutics, Inc. (SRPT) Company Bio

Sarepta Therapeutics is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare, infectious and other diseases. The company was founded in 1980 and is based in Cambridge, Massachusetts.

SRPT Latest News Stream

Event/Time News Detail
Loading, please wait...

SRPT Latest Social Stream

Loading social stream, please wait...

View Full SRPT Social Stream

Latest SRPT News From Around the Web

Below are the latest news stories about Sarepta Therapeutics Inc that investors may wish to consider to help them evaluate SRPT as an investment opportunity.

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2021 financial results after the Nasdaq Global Market closes on Tuesday, March 1, 2022. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2021 financial results and to provide a corporate update.

GlobeNewswire | February 22, 2022

When Can We Expect A Profit From Sarepta Therapeutics, Inc. (NASDAQ:SRPT)?

We feel now is a pretty good time to analyse Sarepta Therapeutics, Inc.'s ( NASDAQ:SRPT ) business as it appears the...

Yahoo | February 22, 2022

U.S. biotech Sarepta loses bid to challenge rival''s muscular dystrophy patents

A Japanese drug maker''s patents related to treating Duchenne muscular dystrophy cannot be challenged by U.S. rival Sarepta Therapeutics before an administrative tribunal, a U.S. appeals court ruled Tuesday.

Reuters | February 8, 2022

Summit Wealth & Retirement Planning, Inc. ...

Investment company Summit Wealth & Retirement Planning, Inc. (Current Portfolio) buys JPMorgan Chase, Alaska Air Group Inc, Starbucks Corp, ETFMG Prime Mobile Payments ETF, Victory Capital Holdings Inc, sells VanEck J.P.

Yahoo | February 3, 2022

Sarepta Bets On GenEdit''s Nanoparticles'' In $57M Gene Editing Partnership

Sarepta Therapeutics Inc (NASDAQ: SRPT ) will pay GenEdit up to $57 million in the near term for access to the biotech''s non-viral delivery platform for gene-editing therapies. Sarepta will combine its gene-editing technology with GenEdit''s NanoGalaxy platform to target up to four neuromuscular indications selected Full story available on

Benzinga | February 1, 2022

Read More 'SRPT' Stories Here

SRPT Price Returns

1-mo -10.70%
3-mo -9.67%
6-mo -13.98%
1-year -8.80%
3-year -43.32%
5-year 128.22%
YTD -23.94%
2021 -47.18%
2020 32.12%
2019 18.24%
2018 96.14%
2017 102.84%

Continue Researching SRPT

Want to see what other sources are saying about Sarepta Therapeutics Inc's financials and stock price? Try the links below:

Sarepta Therapeutics Inc (SRPT) Stock Price | Nasdaq
Sarepta Therapeutics Inc (SRPT) Stock Quote, History and News - Yahoo Finance
Sarepta Therapeutics Inc (SRPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8105 seconds.